


Status: Currently Official on 15-Feb-2025
 Official Date: Official as of 01-Jun-2023
 Document Type: USP Monographs
 DocId: GUID-230A4337-DD08-4631-96C0-DF436EB7378F_5_en-US
 DOI: https://doi.org/10.31003/USPNF_M37440_05_01
 DOI Ref: w4806

© 2025 USPC
 Do not distribute

Histidine



$C_6H_9N_3O_2$ 155.15

L-Histidine CAS RN®: 71-00-1; UNII: 4QD397987E.

DEFINITION

Histidine contains NLT 98.5% and NMT 101.5% of L-histidine ($C_6H_9N_3O_2$), calculated on the dried basis.

IDENTIFICATION

• **A. SPECTROSCOPIC IDENTIFICATION TESTS (197), Infrared Spectroscopy: 197K:** The *Sample* and [USP L-Histidine RS](#) are previously recrystallized from 80% alcohol.

ASSAY

PROCEDURE

Sample: 150 mg of Histidine

Blank: Mix 3 mL of formic acid and 50 mL of glacial acetic acid.

Titrimetric system

(See [Titrimetry \(541\)](#).)

Mode: Direct titration

Titrant: 0.1 N perchloric acid VS

Endpoint detection: Potentiometric

Analysis: Dissolve the *Sample* in 3 mL of formic acid and 50 mL of glacial acetic acid. Titrate very slowly with the *Titrant*. Perform the *Blank* determination.

Calculate the percentage of histidine ($C_6H_9N_3O_2$) in the *Sample* taken:

$$\text{Result} = \{(V_s - V_b) \times N \times F\} / W \times 100$$

V_s = *Titrant* volume consumed by the *Sample* (mL)

V_b = *Titrant* volume consumed by the *Blank* (mL)

N = actual normality of the *Titrant* (mEq/mL)

F = equivalency factor, 155.2 mg/mEq

W = *Sample* weight (mg)

Acceptance criteria: 98.5%–101.5% on the dried basis

IMPURITIES

• [RESIDUE ON IGNITION \(281\)](#): NMT 0.4%

• [CHLORIDE AND SULFATE, Chloride \(221\)](#)

Standard solution: 0.50 mL of 0.020 N hydrochloric acid

Sample: 0.73 g of Histidine

Acceptance criteria: NMT 0.05%

• [CHLORIDE AND SULFATE, Sulfate \(221\)](#)

Standard solution: 0.10 mL of 0.020 N sulfuric acid

Sample: 0.33 g of Histidine

Acceptance criteria: NMT 0.03%

Change to read:

- **▲** [IRON \(241\), Procedures, Procedure 1](#) ▲ (CN 1-JUN-2023) : NMT 30 ppm

• **RELATED COMPOUNDS**

System suitability solution: 0.4 mg/mL each of [USP L-Histidine RS](#) and [USP L-Proline RS](#)

Standard solution: 0.05 mg/mL of [USP L-Histidine RS](#) in water. [NOTE—This solution has a concentration equivalent to 0.5% of the *Sample solution*.]

Sample solution: 10 mg/mL of Histidine in water

Chromatographic system

(See [Chromatography \(621\), Thin-Layer Chromatography](#).)

Mode: TLC

Adsorbent: 0.25-mm layer of chromatographic silica gel mixture

Application volume: 5 µL

Developing solvent system: Butyl alcohol, glacial acetic acid, and water (3:1:1)

Spray reagent: 2 mg/mL of ninhydrin in a mixture of butyl alcohol and 2 N acetic acid (95:5)

System suitability

Suitability requirements: The chromatogram of the *System suitability solution* exhibits two clearly separated spots.

Analysis

Samples: *System suitability solution*, *Standard solution*, and *Sample solution*

After air-drying the plate, spray with *Spray reagent*, and heat between 100° and 105° for 15 min. Examine the plate under white light.

Acceptance criteria: Any secondary spot of the *Sample solution* is not larger or more intense than the principal spot of the *Standard solution*.

Individual impurities: NMT 0.5%

Total impurities: NMT 2.0%

SPECIFIC TESTS

- **OPTICAL ROTATION, Specific Rotation (781S).**

Sample solution: 110 mg/mL in 6 N hydrochloric acid

Acceptance criteria: +12.6° to +14.0°

- **pH (791).**

Sample solution: 20 mg/mL solution

Acceptance criteria: 7.0–8.5

- **LOSS ON DRYING (731):** Dry a sample at 105° for 3 h: it loses NMT 0.2% of its weight.

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in well-closed containers.

- **USP REFERENCE STANDARDS (11).**

[USP L-Histidine RS](#)

[USP L-Proline RS](#)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
HISTIDINE	Fatkhulla K Tadjimukhamedov Associate Scientific Liaison	NBDS2020 Non-botanical Dietary Supplements

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. 49(3)

Current DocID: GUID-230A4337-DD08-4631-96C0-DF436EB7378F_5_en-US

DOI: https://doi.org/10.31003/USPNF_M37440_05_01

OFFICIAL